Measuring the Plasmodium falciparum HRP2 protein in blood from artesunate-treated malaria patients predicts post-artesunate delayed hemolysis

Science Translational Medicine

Volumn 9, Issue 397, 2017, Pages

  Ndour, Papa Alioune ^a,b   Larréché, Sébastien ^c   Mouri, Oussama ^d   Argy, Nicolas ^d   Gay, Frédérick ^d,e   Roussel, Camille ^a,b   Jauréguiberry, Stéphane ^d   Perillaud, Claire ^d   Langui, Dominique ^e   Biligui, Sylvestre ^e   Chartrel, Nathalie ^d   Mérens, Audrey ^c,e   Kendjo, Eric ^d   Ghose, Aniruddha ^f   Hassan, Md Mahtab Uddin ^f   Hossain, Md Amir ^f   Kingston, Hugh W F ^g,h,i   Plewes, Katherine ^g,j   Dondorp, Arjen M ^g,h   Danis, Martin ^d   Houzé, Sandrine ^d   Bonnefoy, Serge ^k   Thellier, Marc ^d,e   Woodrow, Charles J ^g,h   Buffet, Pierre A ^a,b,d   more..

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b Laboratoire d'Excellence GR Ex   (France)

^c SERVICE D ENDOCRINOLOGIE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ERYTHROCYTE ANTIGEN; HISTIDINE RICH PROTEIN 2; MEMBRANE ANTIGEN; MICROORGANISM PROTEIN; QUININE; RING ERYTHROCYTE SURFACE ANTIGEN; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; HRP-2 ANTIGEN, PLASMODIUM FALCIPARUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ADOLESCENT; AFRICA; AGED; ANEMIA; ARTICLE; BANGLADESH; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE; FEMALE; FRENCHMAN; HEMOLYSIS; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MONOTHERAPY; NONHUMAN; PARASITE CLEARANCE; PARASITE MIGRATION; PLASMODIUM FALCIPARUM; POST ARTESUNATE DELAYED HEMOLYSIS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RAPID TEST; RECEIVER OPERATING CHARACTERISTIC; RECOMMENDED DRUG DOSE; REFERENCE VALUE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TRAVEL; VERY ELDERLY; ADULT; BLOOD; CYTOSOL; DEMOGRAPHY; DRUG EFFECTS; ERYTHROCYTE MEMBRANE; MALARIA; METABOLISM; MIDDLE AGED; PARASITOLOGY; PATHOGENICITY; ULTRASTRUCTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, PROTOZOAN; ARTEMISININS; CYTOSOL; DEMOGRAPHY; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; MALARIA; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; QUININE; YOUNG ADULT;

EID: 85021956565     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf9377     Document Type: Article

References (58)

1. WHO, Guidelines for Malaria Treatment (WHO, 2010); http://apps.who.int/medicinedocs/ documents/s19105en/s19105en.pdf.
2. WHO, Information Note on Delayed Haemolytic Anaemia Following Treatment with Artesunate (WHO, 2013); http://www.who.int/malaria/publications/atoz/ who-note-haemolytic-anaemia/en/.
3. K. Rehman, F. Lötsch, P. G. Kremsner, M. Ramharter, Haemolysis associated with the treatment of malaria with artemisinin derivatives: A systematic review of current evidence. Int. J. Infect. Dis. 29, 268-273 (2014).
4. A. Dondorp, F. Nosten, K. Stepniewska, N. Day, N. White; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group, Artesunate versus quinine for treatment of severe falciparum malaria: A randomised trial. Lancet 366, 717-725 (2005).
5. A. M. Dondorp, C. I. Fanello, I. C. E. Hendriksen, E. Gomes, A. Seni, K. D. Chhaganlal, K. Bojang, R. Olaosebikan, N. Anunobi, K. Maitland, E. Kivaya, T. Agbenyega, S. B. Nguah, J. Evans, S. Gesase, C. Kahabuka, G. Mtove, B. Nadjm, J. Deen, J. Mwanga-Amumpaire, M. Nansumba, C. Karema, N. Umulisa, A. Uwimana, O. A. Mokuolu, O. T. Adedoyin, W. B. R. Johnson, A. K. Tshefu, M. A. Onyamboko, T. Sakulthaew, W. P. Ngum, K. Silamut, K. Stepniewska, C. J. Woodrow, D. Bethell, B.Wills,M. Oneko, T. E. Peto, L. von Seidlein, N. P. J. Day, N. J. White; AQUAMAT Group, Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An open-label, randomised trial. Lancet 376, 1647-1657 (2010).
6. S. Jauréguiberry, P. A. Ndour, C. Roussel, F. Ader, I. Safeukui, M. Nguyen, S. Biligui, L. Ciceron, O. Mouri, E. Kendjo, F. Bricaire, M. Vray, A. Angoulvant, J. Mayaux, K. Haldar, D. Mazier, M. Danis, E. Caumes, M. Thellier, P. Buffet; French Artesunate Working Group, Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 124, 167-175 (2014).
7. S. Jauréguiberry, M. Thellier, P. A. Ndour, F. Ader, C. Roussel, R. Sonneville, J. Mayaux, S. Matheron, A. Angoulvant, B. Wyplosz, C. Rapp, T. Pistone, B. Lebrun-Vignes, E. Kendjo, M. Danis, S. Houzé, F. Bricaire, D. Mazier, P. Buffet, E. Caumes; French Artesunate Working Group, Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013. Emerg. Infect. Dis. 21, 804-812 (2015).
8. F. Kurth, M. Develoux, M. Mechain, J. Clerinx, S. Antinori, I. E. Gjørup, J. Gascon, K. Mørch, E. Nicastri, M. Ramharter, A. Bartoloni, L. Visser, T. Rolling, P. Zanger, G. Calleri, J. Salas-Coronas, H. Nielsen, G. Just-Nübling, A. Neumayr, A. Hachfeld, M. L. Schmid, P. Antonini, P. Pongratz, P. Kern, J. Saraivada Cunha, A. Soriano-Arandes, M. Schunk, N. Suttorp, C. Hatz, T. Zoller; TropNet Severe Malaria Investigator Group, Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet Severe Malaria Study. Clin. Infect. Dis. 61, 1441-1444 (2015).
9. T. Zoller, T. Junghanss, A. Kapaun, I. Gjørup, J. Richter, M. Hugo-Persson, K. Mørch, B. Foroutan, N. Suttorp, S. Yürek, H. Flick, Intravenous artesunate for severe malaria in travelers, Europe. Emerg. Infect. Dis. 17, 771-777 (2011).
10. M. M. Paczkowski, K. L. Landman, P. M. Arguin; Centers for Disease Control and Prevention, Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria - United States, 2008 and 2013. MMWR Morb. Mortal. Wkly. Rep. 63, 753-755 (2014).
11. O. Boillat, H. Spechbach, Y. Chalandon, G. Eperon, Post-artesunate delayed haemolysis - Report of four cases and review of the literature. Swiss Med. Wkly. 145, w14181 (2015).
12. P. J. de Vries, C. K. W. van Veldhuizen, A. MaGill, J. Cramer, T. Rolling, P. Arguin, H. Cui, C. Liu, A. Adegnika, T. Zoller, D. Tao, B. Moonen, E. Pelfrene, E. Navarro, E. O'Shaughnessy, H. Shamsuddin, J.-M. Bouchez, L. Fu, L. Su, M. Xiong, P. Buffet, S. Jauréguiberry, B. Mordmüller, C. Köhler, A. Dondorp, T. Agbenyega, O. Doumbo, M. De Smet, M. Narla, A. Bacchieri, Marco Corsi, S. Krishna, C. Hatz, J. Cutler, A. Yohannes, D. Taramelli, A. McCarthy, P. Kremsner, S. Bolte, A. Bosman, P. Olumese, S. Pal, M. Stahl, C. McDermott, B. Smith, D. Reddy, S. Duparc, H. Divecha, P. Hugo, W. Kaszubska, J. Möhrle, Expert Group Meeting on the Safety Profile of Injectable Artesunate, Vienna, Austria, 19 March 2013.
13. K. Plewes, M. S. Haider, H. W. F. Kingston, T. W. Yeo, A. Ghose, M. A. Hossain, A. M. Dondorp, G. D. H. Turner, N. M. Anstey, Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury. Malar. J. 14, 246 (2015).
14. T. Rolling, T. Agbenyega, S. Issifou, A. A. Adegnika, J. Sylverken, D. Spahlinger, D. Ansong, S. J. Z. Löhr, G. D. Burchard, J. May, B. Mordmüller, S. Krishna, P. G. Kremsner, J. P. Cramer, Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria - A double-center prospective study. J. Infect. Dis. 209, 1921-1928 (2014).
15. A. Sowunmi, K. Akano, A. I. Ayede, G. Ntadom, B. Fatunmbi, T. Aderoyeje, E. O. Adewoye, Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children. BMC Infect. Dis. 15, 454 (2015).
16. T. Rolling, D. Wichmann, S. Schmiedel, G. D. Burchard, S. Kluge, J. P. Cramer, Artesunate versus quinine in the treatment of severe imported malaria: Comparative analysis of adverse events focussing on delayed haemolysis. Malar. J. 12, 241 (2013).
17. P. A. Ndour, I. Safeukui, S. Diakhité, J. Duez, S. Jauréguiberry, P. Buffet, Role of Spleen in Human Malaria (Springer, 2015).
18. K. Chotivanich, R. Udomsangpetch, A. Dondorp, T. Williams, B. Angus, J. A. Simpson, S. Pukrittayakamee, S. Looareesuwan, C. I. Newbold, N. J. White, The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J. Infect. Dis. 182, 629-633 (2000).
19. R. J. Howard, S. Uni, M. Aikawa, S. B. Aley, J. H. Leech, A. M. Lew, T. E. Wellems, J. Rener, D. W. Taylor, Secretion of a malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-infected erythrocytes. J. Cell Biol. 103, 1269-1277 (1986).
20. A. M. Dondorp, V. Desakorn, W. Pongtavornpinyo, D. Sahassananda, K. Silamut, K. Chotivanich, P. N. Newton, P. Pitisuttithum, A. M. Smithyman, N. J. White, N. P. J. Day, Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLOS Med. 2, e204 (2005).
21. V. Desakorn, A. M. Dondorp, K. Silamut, W. Pongtavornpinyo, D. Sahassananda, K. Chotivanich, P. Pitisuttithum, A. M. Smithyman, N. P. J. Day, N. J. White, Stagedependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 99, 517-524 (2005).
22. M. D. Silva, B. M. Cooke, M. Guillotte, D. W. Buckingham, J.-P. Sauzet, C. Le Scanf, H. Contamin, P. David, O. Mercereau-Puijalon, S. Bonnefoy, A role for the Plasmodium falciparum RESA protein in resistance against heat shock demonstrated using gene disruption. Mol. Microbiol. 56, 990-1003 (2005).
23. H. Perlmann, K. Berzins, M. Wahlgren, J. Carlsson, A. Björkman, M. E. Patarroyo, P. Perlmann, Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J. Exp. Med. 159, 1686-1704 (1984).
24. P. A. Ndour, T. M. Lopera-Mesa, S. A. S. Diakité, S. Chiang, O. Mouri, C. Roussel, S. Jauréguiberry, S. Biligui, E. Kendjo, A. Claessens, L. Ciceron, D. Mazier, M. Thellier, M. Diakité, R. M. Fairhurst, P. A. Buffet, Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria. J. Infect. Dis. 211, 290-297 (2015).
25. W. Ruangjirachuporn, R. Udomsangpetch, J. Carlsson, D. Drenckhahn, P. Perlmann, K. Berzins, Plasmodium falciparum: Analysis of the interaction of antigen Pf155/RESA with the erythrocyte membrane. Exp. Parasitol. 73, 62-72 (1991).
26. K. Chotivanich, R. Udomsangpetch, R. McGready, S. Proux, P. Newton, S. Pukrittayakamee, S. Looareesuwan, N. J. White, Central role of the spleen in malaria parasite clearance. J. Infect. Dis. 185, 1538-1541 (2002).
27. M. Foley, L. Tilley, W. H. Sawyer, R. F. Anders, The ring-infected erythrocyte surface antigen of Plasmodium falciparum associates with spectrin in the erythrocyte membrane. Mol. Biochem. Parasitol. 46, 137-147 (1991).
28. V. Desakorn, K. Silamut, B. Angus, D. Sahassananda, K. Chotivanich, P. Suntharasamai, J. Simpson, N. J. White, Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans. R. Soc. Trop. Med. Hyg. 91, 479-483 (1997).
29. B. J. Angus, K. Chotivanich, R. Udomsangpetch, N. J. White, In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 90, 2037-2040 (1997).
30. P. A. Buffet, G. Milon, V. Brousse, J.-M. Correas, B. Dousset, A. Couvelard, R. Kianmanesh, O. Farges, A. Sauvanet, F. Paye, M.-N. Ungeheuer, C. Ottone, H. Khun, L. Fiette, G. Guigon, M. Huerre, O. Mercereau-Puijalon, P. H. David, Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 107, 3745-3752 (2006).
31. M. E. Conrad, L. H. Dennis, Splenic function in experimental malaria. Am. J. Trop. Med. Hyg. 17, 170-172 (1968).
32. B. Schnitzer, T. Sodeman, M. L. Mead, P. G. Contacos, Pitting function of the spleen in malaria: Ultrastructural observations. Science 177, 175-177 (1972).
33. S. Jauréguiberry, P. A. Ndour, M. Thellier, E. Caumes, P. Buffet, Patterns of anemia during malaria. Int. J. Infect. Dis. 33, 89 (2015).
34. G. V. Brown, J. G. Culvenor, P. E. Crewther, A. E. Bianco, R. L. Coppel, R. B. Saint, H. D. Stahl, D. J. Kemp, R. F. Anders, Localization of the ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum in merozoites and ring-infected erythrocytes. J. Exp. Med. 162, 774-779 (1985).
35. J. G. Culvenor, K. P. Day, R. F. Anders, Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion. Infect. Immun. 59, 1183-1187 (1991).
36. M. Aikawa, M. Torii, A. Sjölander, K. Berzins, P. Perlmann, L. H. Miller, Pf155/RESA antigen is localized in dense granules of Plasmodium falciparum merozoites. Exp. Parasitol. 71, 326-329 (1990).
37. M. Foley, L. J. Murray, R. F. Anders, The ring-infected erythrocyte surface antigen protein of Plasmodium falciparum is phosphorylated upon association with the host cell membrane. Mol. Biochem. Parasitol. 38, 69-75 (1990).
38. X. Pei, X. Guo, R. Coppel, S. Bhattacharjee, K. Haldar, W. Gratzer, N. Mohandas, X. An, The ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum stabilizes spectrin tetramers and suppresses further invasion. Blood 110, 1036-1042 (2007).
39. WHO, Guidelines for the Treatment of Malaria (2nd Edition) (WHO, 2010); http://apps.who. int/medicinedocs/documents/s19105en/s19105en.pdf.
40. E. Tjitra, S. Suprianto, J. McBroom, B. J. Currie, N. M. Anstey, Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence. J. Clin. Microbiol. 39, 1025-1031 (2001).
41. S. Biswas, D. Tomar, D. N. Rao, Investigation of the kinetics of histidine-rich protein 2 and of the antibody responses to this antigen, in a group of malaria patients from India. Ann. Trop. Med. Parasitol. 99, 553-562 (2005).
42. M. Mayxay, S. Pukrittayakamee, K. Chotivanich, S. Looareesuwan, N. J. White, Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 95, 179-182 (2001).
43. J. Iqbal, A. Siddique, M. Jameel, P. R. Hira, Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance of Plasmodium falciparum monoinfection. J. Clin. Microbiol. 42, 4237-4241 (2004).
44. H. Noedl, C. Wongsrichanalai, R. S. Miller, K. S. A. Myint, S. Looareesuwan, Y. Sukthana, V. Wongchotigul, H. Kollaritsch, G. Wiedermann, W. H. Wernsdorfer, Plasmodium falciparum: Effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp. Parasitol. 102, 157-163 (2002).
45. D. J. Bacon, R. Jambou, T. Fandeur, J. Le Bras, C. Wongsrichanalai, M. M. Fukuda, P. Ringwald, C. H. Sibley, D. E. Kyle, World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility. Malar. J. 6, 120 (2007).
46. L. L. Fox, T. E. Taylor, P. Pensulo, A. Liomba, A. Mpakiza, A. Varela, S. J. Glover, M. J. Reeves, K. B. Seydel, Histidine-rich protein 2 plasma levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection. J. Infect. Dis. 208, 500-503 (2013).
47. A. Sing, E. Rauch, A. Roggenkamp, I. B. Autenrieth, J. Heesemann, Evaluation of the ICT malaria Pf test for rapid post-mortem diagnosis of Plasmodium falciparum malaria in corpses examined for forensic reasons. Int. J. Leg. Med. 113, 251-252 (2000).
48. C. Fernandez-Arias, J. Rivera-Correa, J. Gallego-Delgado, R. Rudlaff, C. Fernandez, C. Roussel, A. Götz, S. Gonzalez, A. Mohanty, S. Mohanty, S. Wassmer, P. Buffet, P. A. Ndour, A. Rodriguez, Anti-self phosphatidylserine antibodies recognize uninfected erythrocytes promoting malarial anemia. Cell Host Microbe 19, 194-203 (2016).
49. J. Baker, J. McCarthy, M. Gatton, D. E. Kyle, V. Belizario, J. Luchavez, D. Bell, Q. Cheng, Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. J. Infect. Dis. 192, 870-877 (2005).
50. D. Gamboa, M.-F. Ho, J. Bendezu, K. Torres, P. L. Chiodini, J. W. Barnwell, S. Incardona, M. Perkins, D. Bell, J. McCarthy, Q. Cheng, A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: Implications for malaria rapid diagnostic tests. PLOS ONE 5, e8091 (2010).
51. N. Kumar, V. Pande, R. M. Bhatt, N. K. Shah, N. Mishra, B. Srivastava, N. Valecha, A. R. Anvikar, Genetic deletion of HRP2 and HRP3 in Indian Plasmodium falciparum population and false negative malaria rapid diagnostic test. Acta Trop. 125, 119-121 (2013).
52. A. B. Deme, D. J. Park, A. K. Bei, O. Sarr, A. S. Badiane, P. E. H. O. Gueye, A. Ahouidi, O. Ndir, S. Mboup, D. F. Wirth, D. Ndiaye, S. K. Volkman, Analysis of pfhrp2 genetic diversity in Senegal and implications for use of rapid diagnostic tests. Malar. J. 13, 34 (2014).
53. R. Udomsangpetch, B. Pipitaporn, S. Krishna, B. Angus, S. Pukrittayakamee, I. Bates, Y. Suputtamongkol, D. E. Kyle, N. J. White, Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J. Infect. Dis. 173, 691-698 (1996).
54. P. M. Arguin, Case definition: Postartemisinin delayed hemolysis. Blood 124, 157-158 (2014).
55. G. A. Farcas, K. J. Zhong, F. E. Lovegrove, C. M. Graham, K. C. Kain, Evaluation of the Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am. J. Trop. Med. Hyg. 69, 589-592 (2003).
56. I. C. E. Hendriksen, L. J. White, J. Veenemans, G. Mtove, C. Woodrow, B. Amos, S. Saiwaew, S. Gesase, B. Nadjm, K. Silamut, S. Joseph, K. Chotivanich, N. P. J. Day, L. von Seidlein, H. Verhoef, H. Reyburn, N. J. White, A. M. Dondorp, Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentration. J. Infect. Dis. 207, 351-361 (2013).
57. P. Perlmann, Immunogenicity assays for clinical trials of malaria vaccines. Parasitol. Today 2, 127-130 (1986).
58. E. S. Reynolds, The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell Biol. 17, 208-212 (1963).